M.B.X. Biosciences (MBX)
Develops precision peptide therapies for endocrine and metabolic disorders.
$58.75
vs last close−3.23 (−5.21%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 115.35% | 55.55M shares | |
|---|---|---|---|
| 182 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.91% | 1.40M shares | |
| 6 holders · as of Aug 5, 2026 | |||
| Adds to | 118.26% | ||
48.16M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 118.26%; nothing is left for Other.
13F, as of Jun 30, 2026
182 holders · 55.55M shares · 43 new positions · 107 increased · 50 reduced · 22 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6.65M | 13.81% | 0 | Aug 14, 2026 |
| FMR LLC | 5.32M | 11.05% | +2.39M | Aug 13, 2026 |
| Wellington Management Group LLP | 4.98M | 10.34% | +1.79M | Aug 14, 2026 |
| Nea Management Company, LLC | 3.61M | 7.51% | 0 | Aug 14, 2026 |
| Orbimed Advisors LLC | 3.43M | 7.12% | −209.2K | Aug 14, 2026 |
| BlackRock, Inc. | 3.32M | 6.90% | +382.3K | Aug 7, 2026 |
| Paradigm Biocapital Advisors LP | 2.51M | 5.21% | +2.51Mnew | Aug 14, 2026 |
| NVP Associates, LLC | 2.14M | 4.44% | 0 | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Patrick J. Heronincl. Fhmls Xi, L.L.C., Fhmls X, L.L.C. +8 more | 11.70% | 5.24M | 13D | Aug 10, 2026 |
| Edward T. Mathersincl. New Enterprise Associates 17, L.P., Ali Behbahani +9 more | 8.10% | 3.62M | 13D | Nov 10, 2025 |
| Wellington Management Group LLP | 7.50% | 3.35M | 13G | Feb 10, 2026 |
| Deep Track Capital, LP | 6.55% | 2.19M | 13G | Aug 14, 2025 |
| Orbimed Advisors LLCincl. Orbimed Genesis GP LLC, Orbimed Capital GP Vii LLC | 6.40% | 3.07M | 13D | Aug 10, 2026 |
| FMR LLC | 6.20% | 2.94M | 13G | May 6, 2026 |
| BlackRock, Inc. | 5.50% | 2.63M | 13G | Jul 29, 2026 |
| Paradigm BioCapital Advisors LP | 5.20% | 2.49M | 13G | Jun 24, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 4, 2026 | Salomon Azoulayofficer: Chief Medical Officer | Sale | 370 | $65.77 | 14,399 |
| May 8, 2026 | Salomon Azoulayofficer: Chief Medical Officer | Sale · 2 lots | 70,003 | $38.36 | 14,769 |
| May 6, 2026 | P. Kent Hawrylukdirector, officer: President & CEO | Sale | 607 | $29.54 | 727,667 |
| May 6, 2026 | Salomon Azoulayofficer: Chief Medical Officer | Sale | 231 | $29.54 | 14,769 |
| Mar 13, 2026 | P. Kent Hawrylukdirector, officer: President & CEO | Purchase | 18,500 | $28.41 | 486,777 |
| Oct 20, 2025 | P. Kent Hawrylukdirector, officer: President & CEO | Purchase | 20,000 | $13.64 | 468,277 |
| Oct 17, 2025 | Steven L. Hoerterdirector | Purchase | 20,000 | $13.25 | 20,000 |
| Sep 26, 2025 | Patrick J. Herondirector, 10 percent owner: | Purchase | 666,666 | $18.00 | 5,219,440 |
House and Senate disclosures
Not reported.